What question did this study set out to answer?

To evaluate the long-term effects of adjuvant tamoxifen therapy on haemostatic alterations and natural anticoagulants that could promote thrombosis.

December 1, 1993Blood Coagulation & Fibrinolysis

The influence of tamoxifen in vivo on the main natural anticoagulants and fibrinolysis

View Full Paper

Ask AI

Bookmark

Authors

KPK. D. Pemberton EME Melissari VKV V Kakkar

Discussion

Member takes

Overview

Randomized trial reveals reduced natural anticoagulant levels during active tamoxifen therapy in post-mastectomy breast cancer patients, suggesting an increased risk of venous thrombosis.

Key Points

To evaluate the long-term effects of adjuvant tamoxifen therapy on haemostatic alterations and natural anticoagulants that could promote thrombosis.
Randomized trial including 149 women who were disease-free for at least 5 years following mastectomy for breast cancer.
Participants were randomized to receive adjuvant tamoxifen for at least 2 years (n = 89) or no adjuvant therapy (n = 60 controls).
Assessed global clotting times, fibrinogen, fibrinolytic factors, and natural anticoagulants (antithrombin III, protein C, protein S), comparing controls, current users (n = 18; median treatment 72 months), and ex-users (n = 71).
Venous thrombosis developed in 5.62% of tamoxifen-treated patients, compared to 0% in the untreated control group.
Current tamoxifen users exhibited significantly lower antithrombin III (P < 0.05) and protein C (P < 0.05) activities compared to ex-users and controls.
Current users showed significantly elevated plasminogen activity (P < 0.01) and tissue plasminogen activator antigen levels (P < 0.01) relative to ex-users and controls.

Cite This Study

Pemberton et al. (1993) studied this question.

synapsesocial.com/papers/6a6fe1c4e71d69abee0840be https://doi.org/10.1097/00001721-199304060-00011

View Full Paper

Ask AI

Bookmark

December 1, 1993Blood Coagulation & Fibrinolysis

The influence of tamoxifen in vivo on the main natural anticoagulants and fibrinolysis

View Full Paper

Ask AI

Bookmark

Authors

KPK. D. Pemberton EME Melissari VKV V Kakkar

Discussion

Member takes

Overview

Randomized trial reveals reduced natural anticoagulant levels during active tamoxifen therapy in post-mastectomy breast cancer patients, suggesting an increased risk of venous thrombosis.

Key Points

To evaluate the long-term effects of adjuvant tamoxifen therapy on haemostatic alterations and natural anticoagulants that could promote thrombosis.
Randomized trial including 149 women who were disease-free for at least 5 years following mastectomy for breast cancer.
Participants were randomized to receive adjuvant tamoxifen for at least 2 years (n = 89) or no adjuvant therapy (n = 60 controls).
Assessed global clotting times, fibrinogen, fibrinolytic factors, and natural anticoagulants (antithrombin III, protein C, protein S), comparing controls, current users (n = 18; median treatment 72 months), and ex-users (n = 71).
Venous thrombosis developed in 5.62% of tamoxifen-treated patients, compared to 0% in the untreated control group.
Current tamoxifen users exhibited significantly lower antithrombin III (P < 0.05) and protein C (P < 0.05) activities compared to ex-users and controls.
Current users showed significantly elevated plasminogen activity (P < 0.01) and tissue plasminogen activator antigen levels (P < 0.01) relative to ex-users and controls.

Cite This Study

Pemberton et al. (1993) studied this question.

synapsesocial.com/papers/6a6fe1c4e71d69abee0840be https://doi.org/10.1097/00001721-199304060-00011

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark